Fig. 4
Addition of YS110 reduced the soluble CD26 production from CD26-positive tumor and non-tumor cells. a, b MM cell lines (MSTO parent, MSTO-CD26, JMN ctrl-shRNA, JMN CD26-shRNA or H226 cells (3.5 × 104, each)) a or non-tumor cells (MCF10A (1.0 × 105), HUVEC (9.0 × 104), MeT-5A (6.0 × 104), TIG-1 (5.0 × 104) or HDMVEC cells (9.0 × 104)) b were incubated with control human IgG (hIgG) or the humanized anti-CD26 mAb YS110 (10 μg/ml, each) for 72 h. c MSTO-CD26 or TIG-1 cells were incubated with the indicated concentrations of YS110 for 3 days. d MSTO-CD26 cells were incubated with the indicated concentrations of YS110 for 1 day, 3 days or 7 days. Concentrations of soluble CD26 in the culture supernatants were examined by ELISA. The dashed line indicates the detection limit (0.488 ng/ml), and ND denotes ‘not detected’ (under detection limit). Representative data of three independent experiments are shown as mean ± S.D. of quadruplicate samples, comparing values with YS110 to those with vehicle or control human IgG (* p < 0.01), and similar results were obtained in each experiment